

## **Extended-Release of Opioids using Fentanyl-based Polymeric Nanoparticles for Enhanced Pain Management**

Marina Kovaliov,<sup>a,b</sup> Shaohua Li,<sup>a,b</sup> Emrullah Korkmaz,<sup>c</sup> Devora Cohen-Karni,<sup>a,b</sup>  
Nestor Tomycz,<sup>b</sup> O. Burak Ozdoganlar,<sup>c,d,e</sup> and Saadyah Averick\*<sup>a,b</sup>

<sup>a</sup>Neuroscience Disruptive Research Lab, Allegheny Health Network Research Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA.

<sup>b</sup>Neuroscience Institute, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA.


<sup>c</sup>Department of Mechanical Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, Pennsylvania 15213, USA

<sup>d</sup>Department of Biomedical Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, Pennsylvania 15213, USA

<sup>e</sup>Department of Materials Science and Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, Pennsylvania 15213, USA


## $^1\text{H}$ NMR spectra of fentanyl initiators

$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )




**Figure S1.**  $^1\text{H}$  NMR spectrum of Fen-OH.

$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )



**Figure S2.**  $^1\text{H}$  NMR spectrum of Fen-Br.

$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )



**Figure S3.**  $^1\text{H}$  NMR spectrum of Fen-Acry-EtOH.

## HPLC spectra of fentanyl initiators




Figure S4 Chromatographic profile of Fen-OH.




Figure S5 Chromatographic profile of Fen-Br.




Figure S6 Chromatographic profile of Fen-Acry-EtOH.

## $^1\text{H}$ NMR spectra of fentanyl polymers




Figure S7  $^1\text{H}$  NMR spectrum of Fen-PLGA.






Figure S8  $^1\text{H}$  NMR spectrum of Fen-Acry-PLGA.

## GPC traces




**Figure S9** GPC trace of Fen-PLGA.




**Figure S10** GPC trace of Fen-Acry-PLGA.


## DLS traces




**Figure S11** Size distribution of Fen-PLA NPs measured by DLS.



**Figure S12** Size distribution of Fen-PLGA NPs measured by DLS.



**Figure S13** Size distribution of Fen-Acry-PLGA NPs measured by DLS.



**Figure S14** Size distribution of Fen-OH-PLGA NPs measured by DLS.



## Zeta potential




Figure S15 Intensity distribution of the zeta potential of Fen-PLA NPs.




Figure S16 Intensity distribution of the zeta potential of Fen-PGLA nanoparticles.






Figure S17 Intensity distribution of the zeta potential of Fen-Acry-PGLA nanoparticles.

**ESEM images**




**Figure S18** ESEM images: (a) Fen-PLA, Fen-PLGA, Fen-Acry-PLGA.

### In vivo activity




**Figure S19** Hot plat test: each point shows the % of MPE induced by fentanyl at different concentrations.



**Figure S20** The change in mouse weight throughout the testing period.

### Dissolvable microneedle arrays (MNA)



**Figure S21** Tip-loaded dissolvable MNAs created using the micromilling/elastomer molding/spin-casting technique for patient-friendly delivery of opioid biohybrids in skin: (a) Optical microscope images of the elastomer mold after tip loading with the NPs; and (b) bright field microscope images of the tip-loaded dissolvable MNAs along with merged bright field and fluorescence microscope image of the tip portion of the individual microneedle.